Bibliographic citations
Quispe, D., Rivera, M. (2021). Mortalidad en pacientes con Sarcoma de Kaposi que recibieron tratamiento oncológico junto al Tratamiento Antirretroviral en tres hospitales públicos de Lima, Perú, 2008-2018 [Tesis, Universidad Peruana de Ciencias Aplicadas (UPC)]. http://hdl.handle.net/10757/655561
Quispe, D., Rivera, M. Mortalidad en pacientes con Sarcoma de Kaposi que recibieron tratamiento oncológico junto al Tratamiento Antirretroviral en tres hospitales públicos de Lima, Perú, 2008-2018 [Tesis]. PE: Universidad Peruana de Ciencias Aplicadas (UPC); 2021. http://hdl.handle.net/10757/655561
@misc{renati/1289748,
title = "Mortalidad en pacientes con Sarcoma de Kaposi que recibieron tratamiento oncológico junto al Tratamiento Antirretroviral en tres hospitales públicos de Lima, Perú, 2008-2018",
author = "Rivera Castillo, Mirtha Patricia",
publisher = "Universidad Peruana de Ciencias Aplicadas (UPC)",
year = "2021"
}
Introduction: Kaposi's Sarcoma (KS) is a neoplastic disease caused by Herpesvirus 8 in synergy with HIV. Currently, there is no treatment with scientific evidence to support its effectiveness and decrease in mortality. Objective: Assess whether the use of cancer treatment reduces mortality three years after starting ART in patients with HIV and KS. Materials and methods: An analytical cross-sectional study was conducted in three national hospitals between 2008 and 2018. KS patients were divided between those who received ART and those who received ART with cancer treatment. The clinical history and the ART file were reviewed. Results: The population mean was 45,02 years for low-risk patients (SD: 12,56). In the bivariate analysis, a significant association was found between mortality and abandonment of ART (p=0,046). No significant association was identified between mortality and initial treatment, be it cancer treatment plus ART or ART alone (PR: 0,92; 95% CI 0,326;2,575). In the adjusted model, no significant association was observed between the variables Death Event and Treatment. Conclusions: Cancer treatment does not reduce mortality three years after starting ART in patients with HIV and KS. There is an increase in mortality in patients with HIV and KS who abandon ART. KS Staging, Initial CD4 Range, Sexual Orientation, among others, were not influential in mortality. 27.9% of patients with HIV and KS died during the study period. There are several factors that increase the incidence of HIV and KS.
This item is licensed under a Creative Commons License